[1]陈余英,周小花,陈晓文,等.乳腺浸润性导管癌中ER、PR、Her-2、Ki-67表达与病理特征及预后的相关性[J].医学信息,2020,33(01):68-71.[doi:10.3969/j.issn.1006-1959.2020.01.022]
　CHEN Yu-ying,ZHOU Xiao-hua,CHEN Xiao-wen,et al.Correlation of ER,PR,Her-2,Ki-67 Expression with Pathological Features and Prognosis in Invasive Ductal Carcinoma of the Breast[J].Medical Information,2020,33(01):68-71.[doi:10.3969/j.issn.1006-1959.2020.01.022]
点击复制

乳腺浸润性导管癌中ER、PR、Her-2、Ki-67表达与病理特征及预后的相关性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年01期
页码:
68-71
栏目:
论著
出版日期:
2020-01-01

文章信息/Info

Title:
Correlation of ER,PR,Her-2,Ki-67 Expression with Pathological Features and Prognosis in Invasive Ductal Carcinoma of the Breast
文章编号:
1006-1959（2020）01-0068-05
作者:
陈余英1; 周小花1; 陈晓文2; 吴 华2
（1.广东医科大学研究生学院，广东 湛江 524000；2.广东医科大学附属医院肿瘤中心，广东 湛江 524000）
Author(s):
CHEN Yu-ying1; ZHOU Xiao-hua1; CHEN Xiao-wen2; WU Hua2
(1.Graduate School of Guangdong Medical University,Zhanjiang 524000,Guangdong,China;2.Cancer Center,the Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,Guangdong,China)
关键词:
乳腺癌; 预后; Ki-67; ER; PR; Her-2
Keywords:
Breast cancer; Prognosis; Ki67; ER; PR; Her-2
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2020.01.022
文献标志码:
A
摘要:
目的 探究Ki-67、ER、PR、Her-2等基因在乳腺浸润性导管癌（IDC）组织中的表达，分析其与患者临床病理特征及预后的相关性。方法 收集2013年1月~2014年12月广东医科大学附属医院病理科乳腺包埋石蜡块IDC组织74例。采用免疫组织化学法检测ER、PR、Her-2、Ki-67在IDC组织中的表达，分析其与患者年龄、组织学分级、TNM分期、淋巴结转移及预后的相关性。结果 ①不同年龄、组织学分级、淋巴结转移及TNM分期的IDC患者ER、PR表达情况比较，差异均无统计学意义（P＞0.05）；未发生淋巴结转移的IDC患者Her-2表达低于转移患者，差异有统计学意义（P＜0.05）；不同年龄、组织学分级、TNM分期的IDC患者Her-2表达比较，差异无统计学意义（P＞0.05）；不同TNM分期的IDC患者Ki-67表达情况比较，差异有统计学意义（P＜0.05），不同年龄、组织学分级、淋巴结转移的IDC患者Ki-67表达比较，差异均无统计学意义（P＞0.05）。 ②Spearman相关性分析显示，ER与PR正相关，ER与Her-2、PR与Her-2负相关，ER、Ki-67和PR、Ki-67负相关，Her-2与Ki-67正相关。③Ki-67阳性表达的IDC患者病死率高于Ki-67阴性表达的患者，差异有统计学意义（P＜0.05）；不同ER、PR、Her-2表达情况的IDC患者病死率比较，差异无统计学意义（P＞0.05）；Ki-67阴性表达患者的总生存时间（OS）高于阳性表达患者，COX多因素分析显示，Ki-67阳性表达是影响IDC患者OS的独立因素（95%CI：0.212~0.865，P=0.018）。结论 Ki-67可作为乳腺浸润性导管癌危险评估的分子标志物，其阳性表达可影响乳腺癌患者的预后。ER、PR、Her-2的表达对乳腺浸润性导管癌患者的预后没有明显影响。
Abstract:
Objective To investigate the expression of Ki-67, ER, PR, Her-2 and other genes in breast invasive ductal carcinoma (IDC) tissues, and to analyze their correlation with the clinicopathological characteristics and prognosis of patients. Methods From January 2013 to December 2014, 74 cases of IDC tissues with breast paraffin embedded in the Department of Pathology, Affiliated Hospital of Guangdong Medical University were collected. Immunohistochemical methods were used to detect the expression of ER, PR, Her-2, and Ki-67 in IDC tissues, and their correlation with patient age, histological grade, TNM stage, lymph node metastasis, and prognosis were analyzed.Results ①There was no significant difference in ER and PR expression between IDC patients with different age, histological grade, lymph node metastasis and TNM stage (P>0.05). Her-2 expression in IDC patients without lymph node metastasis was lower than that in metastatic patients,the difference was statistically significant (P<0.05); there was no significant difference in Her-2 expression among IDC patients of different ages, histological grades, and TNM stages (P>0.05). Ki-67 expression in IDC patients with different TNM stages was statistically significant (P<0.05), and Ki-67 expression in IDC patients with different ages, histological grades, and lymph node metastasis was not statistically significant (P>0.05).②Spearman correlation analysis showed that ER was positively correlated with PR, ER was negatively correlated with Her-2, PR was negatively correlated with Her-2, ER, Ki-67 was negatively correlated with PR, Ki-67, and Her-2 was positively correlated with Ki-67.③The mortality of IDC patients with Ki-67 positive expression was higher than that of Ki-67 negative expression, the difference was statistically significant (P<0.05). There was no significant difference in mortality among IDC patients with different expressions of ER, PR, and Her-2 (P>0.05); the overall survival time (OS) of patients with Ki-67 negative expression was higher than those with positive expression, and COX was multifactor Analysis showed that Ki-67 positive expression was an independent factor affecting OS in patients with IDC (95%CI: 0.212~0.865, P=0.018).Conclusion Ki-67 can be used as a molecular marker for the risk assessment of breast invasive ductal carcinoma, and its positive expression can affect the prognosis of breast cancer patients. The expressions of ER, PR, and Her-2 did not significantly affect the prognosis of patients with invasive ductal carcinoma of the breast.

参考文献/References:

[1]Elkablawy MA,Albasri AM,Mohammed RA,et al.Ki67 expression in breast cancer:Correlation with prognostic makers and clinical pathological parameters in Saudi patients[J].Saudi Med J,2016,37(2):137-141. [2]王增燕,吴雄,杨乐艺.Ki67在早期乳腺癌中的表达及临床意义[J].中国继续医学教育,2015,7(24):56-57. [3]周晨阳,黄月英,范天苗,等.三阴性乳腺癌中CK5/6与Ki-67的表达及其与患者临床病理特征的相关性[J].华中科技大学学报（医学版）,2019,48(2):225-227. [4]Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25(1):118-145． [5]顾蓓,郭斌,石国建,等.4种生物学因子对局部晚期乳腺癌新辅助化疗疗效评估的价值[J].解剖学报,2019,50(3):329-333. [6]原庆会,何伟,王安群,等.乳腺癌组织中ER、PR、HER-2、BRCA-1的表达情况及与远期预后的关系[J].医学综述,2015, 21(4):722-723,726. [7]王耀辉,高丽丽,王晨曦,等.ER,PR,Her-2及Ki-67在乳腺癌原发灶和前哨淋巴结转移灶中的表达对比研究[J].现代肿瘤医学,2019,27(6):959-963. [8]Gerdes J,Schwab U,Lemke H,et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation[J].Int J Caner,1983,31(1):13-20. [9]王娟,黄炳臣,吴雪铭,等.ER、PR、Her-2、VEGF、p53和Ki67在乳腺癌中的表达及临床病理意义分析[J].右江医学,2019,47(3):166-171. [10]Junnan X,Xiangyu G,Mingxi J,et al.Prediction of tumor mutation burden in breast cancer based on the expression of ER,PR,HER-2,and Ki-67[J].OncoTargets and therapy,2018(11):2269-2275. [11]杨虹,曾福仁,刘剑仑,等.ER、PR、HER-2、Ki-67与乳腺癌新辅助化疗疗效相关性分析[J].中国现代医学杂志,2016,26(24):54-57. [12]韦晓霞,姜瑞瑞,雷婷,等.RT-qPCR法定量检测乳腺癌FFPE样本ER、PR、HER2、Ki-67表达的初步分析[J].临床与实验病理学杂志,2018,34(9):968-971. [13]张燕娜,周易冬,茅枫,等.孕激素受体与Ki-67指数组合对激素受体阳性中分化早期乳腺癌预后的评估价值[J].协和医学杂志,2019,10(5):539-545. [14]冯轲昕,王翔,王昕.增殖细胞核抗原Ki-67及其在新辅助化疗前后的变化与乳腺癌预后的关系[J].癌症进展,2019,17(13):1494-1497,1582. [15]王宝娜,王翔,王靖,等.Ki67在乳腺癌中的表达及临床意义[J].中华肿瘤杂志,2014,36(4):273-275. [16]Goldhirsch A,Ingle JN,Gelber RD,et al.Thresholds for therapies: highlights of the StGallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009[J].Ann Oncol,2009,20(8):1319-1329. [17]张功学,齐峰,丁凯,等.Ki67、Her-2及EGFR在乳腺癌组织中表达的临床意义[J].标记免疫分析与临床,2018,25(3):375-379. [18]孙秀玲.浸润性乳腺癌HER-2蛋白过表达人群中ER、PR的表达及与HER-2基因扩增之间的相关性[J].中国妇幼保健,2015,30(24):4226-4228. [19]于喜法,秦合军.ER、PR、C-erbB-2、P53和 Ki-67在乳腺癌组织中的表达及与其临床病理特征相关性[J].实用癌症杂志,2018,33(1):39-42.

相似文献/References:

[1]张西园.糖尿病与结直肠癌患者预后相关研究进展[J].医学信息,2018,31(01):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
　ZHANG Xi-yuan.Research Progress in the Relationship between Diabetes and the Prognosis of Colorectal Cancer[J].Medical Information,2018,31(01):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
[2]张林.围术期输血对胃癌根治术患者预后及免疫的影响[J].医学信息,2018,31(01):94.[doi:10.3969/j.issn.1006-1959.2018.01.033]
　ZHANG Lin.Effect of Perioperative Blood Transfusion on Prognosis and Immunity of Patients with Radical Gastrectomy[J].Medical Information,2018,31(01):94.[doi:10.3969/j.issn.1006-1959.2018.01.033]
[3]及预后罗华.白内障术后眼内炎的危险因素分析[J].医学信息,2018,31(01):108.[doi:10.3969/j.issn.1006-1959.2018.01.040]
　LUO Hua.Risk Factors and Prognosis of Endophthalmitis after Cataract Surgery[J].Medical Information,2018,31(01):108.[doi:10.3969/j.issn.1006-1959.2018.01.040]
[4]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
　DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,31(01):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[5]李 轩,王子为,赵靖萱,等.肿瘤预后预测领域机器学习应用的文献计量与热点可视化分析[J].医学信息,2022,35(09):90.[doi:10.3969/j.issn.1006-1959.2022.09.023]
　LI Xuan,WANG Zi-wei,ZHAO Jing-xuan,et al.Visualization Analysis on Bibliometrics and Hot Spots of Machine Learning Applications in the Field of Tumor Prognosis Prediction[J].Medical Information,2022,35(01):90.[doi:10.3969/j.issn.1006-1959.2022.09.023]
[6]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
　ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Medical Information,2022,35(01):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[7]倪凤媛,李青山,刘兰芳,等.复发转移乳腺癌首发转移模式及预后影响因素[J].医学信息,2018,31(12):1.[doi:10.3969/j.issn.1006-1959.2018.12.001]
　NI Feng-yuan,LI Qing-shan,LIU Lan-fang,et al.The First Metastatic Model of Metastatic Breast Cancer and the Influencing Factors of its Prognosis[J].Medical Information,2018,31(01):1.[doi:10.3969/j.issn.1006-1959.2018.12.001]
[8]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[9]施雨南,陈志平,肖秋香,等.KAI1、Snail、Slug、E-cadherin在鼻咽癌中的表达及其与患者预后的关系[J].医学信息,2022,35(11):77.[doi:10.3969/j.issn.1006-1959.2022.11.021]
　SHI Yu-nan,CHEN Zhi-ping,XIAO Qiu-xiang,et al.The Expression of KAI1, Snail, Slug, and E-cadherin in Nasopharyngeal Carcinoma and its Relationship with the Prognosis of patients[J].Medical Information,2022,35(01):77.[doi:10.3969/j.issn.1006-1959.2022.11.021]
[10]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
　YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,31(01):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[11]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,31(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
　ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Medical Information,2018,31(01):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[12]王雪莲,郭宝良.PLR与乳腺癌预后的关系[J].医学信息,2020,33(06):40.[doi:10.3969/j.issn.1006-1959.2020.06.012]
　WANG Xue-lian,GUO Bao-liang.The Relationship Between PLR and Breast Cancer Prognosis[J].Medical Information,2020,33(01):40.[doi:10.3969/j.issn.1006-1959.2020.06.012]
[13]陈睿鹏,臧洪婧,孙 意.基于焦亡相关基因构建乳腺癌预后风险模型[J].医学信息,2023,36(02):1.[doi:10.3969/j.issn.1006-1959.2023.02.001]
　CHEN Rui-peng,ZANG Hong-jing,SUN Yi.Construction of A Breast Cancer Prognostic Risk Model Based on Pyroptosis-related Genes[J].Medical Information,2023,36(01):1.[doi:10.3969/j.issn.1006-1959.2023.02.001]

更新日期/Last Update: 2020-01-01